Status:
COMPLETED
A Post-Intervention Surveillance Study Regarding the Acquisition Rate of ESBL-KP, Ecoli
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Infection
Eligibility:
All Genders
18+ years
Brief Summary
To determine the acquisition rate of ESBL producing E. coli or K. pneumoniae, post- intervention in the selected medical centres
Detailed Description
This is post-interventional study to follow the acquisition rate of ESBP producing E. coli or K. pneumoniae at the sites involved in a previous interventional study.
Eligibility Criteria
Inclusion
- Inclusion
- All patients admitted or transferred to ICU/burn unit.
- Patients of either sex, 18 years of age or older. Exclusion
- Patients were excluded if they had underlying conditions or diseases that were ultimately fatal within 48 hours
Exclusion
Key Trial Info
Start Date :
December 1 2003
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2004
Estimated Enrollment :
256 Patients enrolled
Trial Details
Trial ID
NCT00724919
Start Date
December 1 2003
End Date
April 1 2004
Last Update
August 11 2008
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Miaoli County, Taiwan, 351
2
Taichung, Taiwan, 40705